Selinexor Plus Ruxolitinib for Myelofibrosis

Selinexor Plus Ruxolitinib for Myelofibrosis
98%54%10%Mar 16Mar 17Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30Mar 31Apr 1Apr 2Apr 3Apr 4Apr 5Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25May 21 • YES 63.5%May 22 • YES 64.2%May 23 • YES 23.8%May 24 • YES 33.9%May 25 • YES 83.3%
Karyopharm Therapeutics Inc ($KPTI)
No stock closeNo stock close$9.05$7.00$4.94Mar 16Mar 17Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30Mar 31Apr 1Apr 2Apr 3Apr 4Apr 5Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25Mar 16 • KPTI $8.55Mar 17 • KPTI $8.38Mar 18 • KPTI $8.40Mar 19 • KPTI $7.73Mar 20 • KPTI $7.63Mar 23 • KPTI $6.66Mar 24 • KPTI $5.44
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Resolved Date
3/24/26
Study Completion
3/1/28
Sponsor
Karyopharm Therapeutics Inc
Ticker
$KPTI
Type
Phase 3
Trial Status
Active, not recruiting
Trial Size
353
NCT
NCT04562389
Trial Description
Selinexor plus ruxolitinib is being tested in people with JAK inhibitor-naïve myelofibrosis for spleen shrinkage and symptom improvement.